title: The Evaluation of the Impact of Age, Skin Tags, Metabolic Syndrome, Body Mass Index, and Smoking on Homocysteine, Endothelin-1, High-sensitive C-reactive Protein, and on the Heart.
abstract: BACKGROUND
  Skin tags (STs) are small, pedunculated skin-colored or brown papules that occur around any site where skin folds occur. The literature is short of comprehensive and controlled clinical studies aimed to evaluate the atherogenic risk factors in patients with STs.
  
  
  OBJECTIVE
  The aim of this study is to evaluate the impact of age, STs, metabolic syndrome (METs), body mass index (BMI), and smoking on homocysteine (Hcy), endothelin-1 (ET-1), high-sensitive C-reactive protein (Hs-CRP), and on cardiovascular diseases.
  
  
  METHODS
  This study included 30 cardiac patients with STs, 30 non-cardiac patients with STs, and 30 healthy controls with neither heart disease nor STs. History of smoking, measurement of height, weight, BMI, waist circumference (WC), blood pressure, STs number, color, acanthosis nigricans, estimation of serum level of fasting glucose, triglycerides (TGs), cholesterol, high-dense lipoproteins (HDL), Hcy, ET-1, Hs-CRP, and the presence of the METs were elicited in the three groups.
  
  
  RESULTS
  Regarding the Hcy, ET-1, and Hs-CRP, the cardiac-STs group showed the highest levels and the control group showed the least (P < 0.001). The percents of patients with METs were 56.7% in the cardiac-STs, 40% in the non-cardiac-STs, and 0% in the control group (P < 0.001). Mean BMI exceeded the limit of obesity in the cardiac-STs group (30.9 ± 3.9) and the non-cardiac-STs group (32.6 ± 6) and was normal in the control group (24.7 ± 2.8). Hyperpigmented STs were present in 66.7% of the cardiac-STs group. Multivariate regression analysis for the independent effectors on Hcy level were the presence of STs (P < 0.001), METs (P = 0.001), and BMI (P = 0.024). Regarding ET-1, the effectors were the presence of STs and METs (P = 0.032). For Hs-CRP, effectors were the presence of STs (P < 0.001) and smoking (P = 0.040). Multivariate logistic regression of the predictors of cardiac disease showed that the independent predictors of the occurrence of cardiac disease were BMI (P < 0.001), STs (P = 0.002), and METs (P = 0.037).
  
  
  CONCLUSIONS
  STs may act as a physical sign of underlying raised cardiac atherogenic factors. This may indicates an ongoing risk on coronary circulation which may indicate further corrective action, hopefully early enough. The association of ST with obesity and METs represents a Bermuda Triangle that act against the heart.
authors.affiliation: Department of Dermatology, Cairo University, Cairo, Egypt.
authors.forename: Omar Soliman
authors.initials: OS
authors.lastname: El Safoury
authors.forename: Marwa
authors.initials: M
authors.lastname: Ezzat
authors.forename: Mahmoud F
authors.initials: MF
authors.lastname: Abdelhamid
authors.forename: Nadia
authors.initials: N
authors.lastname: Shoukry
authors.forename: Ehssan
authors.initials: E
authors.lastname: Badawy
keywords: Blood pressure; cardiac risk factors; cholesterol; endothelin-1; high-dense lipoproteins; high-sensitive C-reactive protein; homocysteine; metabolic syndrome; obesity; skin tags; smoking; triglycerides; waist circumference
references.citation: Indian J Dermatol Venereol Leprol. 2011 Sep-Oct;77(5):577-80
references.pmid: 21860156
references.citation: Atherosclerosis. 2006 Aug;187(2):415-22
references.pmid: 16257408
references.citation: Clin Chem. 2000 Nov;46(11):1839-42
references.pmid: 11067823
references.citation: Indian J Dermatol. 2011 Jul;56(4):393-7
references.pmid: 21965846
references.citation: J Clin Pathol. 2000 Nov;53(11):873-4
references.pmid: 11127274
references.citation: Obes Res. 1999 May;7(3):299-302
references.pmid: 10348502
references.citation: Circulation. 2004 Jan 27;109(3):433-8
references.pmid: 14744958
references.citation: An Bras Dermatol. 2010 Jan-Feb;85(1):25-31
references.pmid: 20464083
references.citation: Curr Hypertens Rep. 2005 Apr;7(2):88-95
references.pmid: 15748531
references.citation: J Clin Invest. 1976 Apr;57(4):1079-82
references.pmid: 947949
references.citation: Mayo Clin Proc. 2008 Nov;83(11):1203-12
references.pmid: 18990318
references.citation: Clin Exp Med. 2010 Sep;10(3):193-7
references.pmid: 20033751
references.citation: Indian J Dermatol. 2010;55(1):20-4
references.pmid: 20418971
references.citation: J Dermatol. 2005 May;32(5):371-5
references.pmid: 16043900
references.citation: Circulation. 1995 Nov 1;92(9):2426-31
references.pmid: 7586341
references.citation: J Hypertens. 2005 Feb;23(2):233-46
references.pmid: 15662207
references.citation: Indian J Dermatol Venereol Leprol. 1996 Jul-Aug;62(4):226-8
references.pmid: 20948060
references.citation: Pharmacol Rev. 2002 Dec;54(4):599-618
references.pmid: 12429870
references.citation: J Eur Acad Dermatol Venereol. 2012 Dec;26(12):1552-7
references.pmid: 22188415
references.citation: Nutr Metab (Lond). 2011 Mar 28;8(1):19
references.pmid: 21443784
references.citation: Res Commun Chem Pathol Pharmacol. 1994 Jun;84(3):271-81
references.pmid: 7938901
references.citation: Arch Intern Med. 2002 Jun 24;162(12):1374-81
references.pmid: 12076236
references.citation: Circulation. 2003 Jan 28;107(3):499-511
references.pmid: 12551878
references.citation: Dermatologica. 1987;174(4):180-3
references.pmid: 3582706
references.citation: J Cardiovasc Pharmacol. 2007 Dec;50(6):621-8
references.pmid: 18091577
references.citation: Clin Chem. 2000 Feb;46(2):265-72
references.pmid: 10657384